Using epitope predictions to evaluate efficacy and population coverage of the Mtb72f vaccine for tuberculosis

BMC Immunology

Volumn 11, Issue , 2010, Pages

  McNamara, Lucy A ^a,b   He, Yongqun ^b,c   Yang, Zhenhua ^a  

^a UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; EPITOPE; HLA DR ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; SUBUNIT VACCINE; DEVELOPMENTALLY REGULATED RNA BINDING PROTEIN 1, HUMAN; DEVELOPMENTALLY REGULATED RNA-BINDING PROTEIN 1, HUMAN; NERVE PROTEIN; RNA BINDING PROTEIN;

ALLELE; AMINO ACID SEQUENCE; ARTICLE; BACTERIUM ISOLATE; COMPUTER MODEL; COMPUTER PROGRAM; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESEARCH; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HOST RESISTANCE; INFECTION PREVENTION; MYCOBACTERIUM TUBERCULOSIS; POPULATION GENETICS; PREDICTION; PROTEIN BINDING; TUBERCULOSIS; ALGORITHM; BIOLOGICAL MODEL; GENETICS; HUMAN; IMMUNOLOGY;

ALGORITHMS; EPITOPES, T-LYMPHOCYTE; GENOTYPE; HUMANS; MODELS, IMMUNOLOGICAL; NERVE TISSUE PROTEINS; RNA-BINDING PROTEINS; TUBERCULOSIS; TUBERCULOSIS VACCINES; VACCINES, SUBUNIT;

EID: 77950380847     PISSN: None     EISSN: 14712172     Source Type: Journal    
DOI: 10.1186/1471-2172-11-18     Document Type: Article

References (55)

1. Anderson P. Tuberculosis -- an update. Nat Rev Micro 2007, 5(7):484-487.
2. Hoft DF. Tuberculosis vaccine development: goals, immunological design, and evaluation. Lancet 2008, 372(9633):164-175. 10.1016/S0140-6736(08)61036-3, 18620952.
3. Brennan MJ, Fruth U, Milstien J, Tiernan R, de Andrade Nishioka S, Chocarro L. Development of new tuberculosis vaccines: a global perspective on regulatory issues. PLoS Med 2007, 4(8):e252. 10.1371/journal.pmed.0040252, 1939860,1939860, 17683198.
4. De Groot AS, McMurry J, Marcon L, Franco J, Rivera D, Kutzler M, Weiner D, Martin B. Developing an epitope-driven tuberculosis (TB) vaccine. Vaccine 2005, 23:2121-2131. 10.1016/j.vaccine.2005.01.059, 15755582.
5. Skeiky YA, Alderson MR, Ovendale PJ, Guderian JA, Brandt L, Dillon DC, Campos-Neto A, Lobet Y, Dalemans W, Orme IM, et al. Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J Immunol 2004, 172(12):7618-7628.
6. Dillon DC, Alderson MR, Day CH, Lewinsohn DM, Coler R, Bement T, Campos-Neto A, Skeiky YA, Orme IM, Roberts A, et al. Molecular characterization and human T-cell responses to a member of a novel Mycobacterium tuberculosis mtb39 gene family. Infect Immun 1999, 67(6):2941-2950. 96604, 10338503.
7. Reed SG, Coler RN, Dalemans W, Tan EV, DeLa Cruz EC, Basaraba RJ, Orme IM, Skeiky YA, Alderson MR, Cowgill KD, et al. Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys. Proc Natl Acad Sci USA 2009, 106(7):2301-2306. 10.1073/pnas.0712077106, 2650151, 19188599.
8. Hebert AM, Talarico S, Yang D, Durmaz R, Marrs CF, Zhang L, Foxman B, Yang Z. DNA polymorphisms in the pepA and PPE18 genes among clinical strains of Mycobacterium tuberculosis: implications for vaccine efficacy. Infect Immun 2007, 75(12):5798-5805. 10.1128/IAI.00335-07, 2168324, 17893137.
9. Kimman TG, Vandebriel RJ, Hoebee B. Genetic variation in the response to vaccination. Community Genet 2007, 10(4):201-217. 10.1159/000106559, 17895626.
10. Gey van Pittius NCSLS, Lee H, Kim Y, van Helden PD, Warren RM. Evolution and expansion of the Mycobacterium tuberculosis PE and PPE multigene families and their association with the duplication of the ESAT-6 (esx) gene cluster regions. BMC Evolutionary Biology 2006, 6:95. 10.1186/1471-2148-6-95, 1660551, 17105670.
11. Nielsen M, Lundegaard C, Blicher T, Peters B, Sette A, Justesen S, Buus S, Lund O. Quantitative predictions of peptide binding to any HLA-DR molecule of known sequence: NetMHCIIpan. PLoS Comput Biol 2008, 4(7):e1000107. 10.1371/journal.pcbi.1000107, 2430535, 18604266.
12. Lin HH, Ray S, Tongchusak S, Reinherz EL, Brusic V. Evaluation of MHC class I peptide binding prediction servers: Applications for vaccine research. BMC Immunol 2008, 9(1). 2323361, 18366636.
13. Lin HH, Zhang GL, Tongchusak S, Reinherz EL, Brusic V. Evaluation of MHC-II peptide binding prediction servers: applications for vaccine research. BMC Bioinformatics 2008, 9(Suppl 12):S22. 10.1186/1471-2105-9-S12-S22, 2638162, 19091022.
14. Gowthaman U, Agrewala JN. In Silico Tools for Predicting Peptides Binding to HL-Class II Molecules: More Confusion than Conclusion. J Proteome Res 2008, 7(1):154-163. 10.1021/pr070527b, 18034454.
15. Wang P, Sidney J, Dow C, Mothe B, Sette A, Peters B. A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach. PLoS Comput Biol 2008, 4(4):e1000048. 10.1371/journal.pcbi.1000048, 2267221, 18389056.
16. Trost B, Bickis M, Kusalik A. Strength in numbers: achieving greater accuracy in MHC-I binding prediction by combining the results from multiple prediction tools. Immunome Res 2007, 3:5. 10.1186/1745-7580-3-5, 1847428, 17381846.
17. Wang Y, Smith JA, Kamradt T, Gefter ML, Perkins DL. Silencing of immunodominant epitopes by contiguous sequences in complex synthetic peptides. Cell Immunol 1992, 143(2):284-297. 10.1016/0008-8749(92)90026-L, 1380894.
18. Bloom BR, Fine PEM. The BCG experience: implications for future vaccines against tuberculosis. Tuberculosis: protection, pathogenesis, and control 1994, Washington, DC: ASM Press.
19. Fleischmann R, Alland D, Eisen J, Carpenter L, White O, Peterson J, DeBoy R, Dodson R, Gwinn M, Haft D, et al. Whole-genome comparion of Mycobacterium tuberculosis clinical and laboratory strains. J Bacteriol 2002, 184(19):5479-5490. 10.1128/JB.184.19.5479-5490.2002, 135346, 12218036.
20. Ribeiro-Guimaraes ML, Pessolani MCV. Comparative genomics of mycobacterial proteases. Microbial Pathogenesis 2007, 43:173-178. 10.1016/j.micpath.2007.05.010, 17611072.
21. Bui HH, Sidney J, Li W, Fusseder N, Sette A. Development of an epitope conservancy analysis tool to facilitate the design of epitope-based diagnostics and vaccines. BMC Bioinformatics 2007, 8:361. 10.1186/1471-2105-8-361, 2233646, 17897458.
22. McMurry J, Sbai H, Gennaro ML, Carter EJ, Martin W, De Groot AS. Analyzing Mycobacterium tuberculosis proteomes for candidate vaccine epitopes. Tuberculosis (Edinb) 2005, 85(1-2):95-105. 10.1016/j.tube.2004.09.005, 15687033.
23. Reche PA, Glutting JP, Reinherz EL. Prediction of MHC class I binding peptides using profile motifs. Hum Immunol 2002, 63(9):701-709. 10.1016/S0198-8859(02)00432-9, 12175724.
24. Shams H, Klucar P, Weis SE, Lalvani A, Moonan PK, Safi H, Wizel B, Ewer K, Nepom GT, Lewinsohn DM, et al. Characterization of a Mycobacterium tuberculosis peptide that is recognized by human CD4+ and CD8+ T cells in the context of multiple HLA alleles. J Immunol 2004, 173(3):1966-1977.
25. Allele Frequencies in Worldwide Populations Database. , http://www.allelefrequencies.net/
26. Organization WH Global tuberculosis control - epidemiology, strategy, financing. 2009, 411. Geneva: Wolrd HealthOrganization, Organization WH.
27. Weichold FF, Mueller S, Kortsik C, Hitzler WE, Wulf MJ, Hone DM, Sadoff JC, Maeurer MJ. Impact of MHC class I alleles on the M. tuberculosis antigen-specific CD8+ T-cell response in patients with pulmonary tuberculosis. Genes Immun 2007, 8(4):334-343. 10.1038/sj.gene.6364392, 17429413.
28. Blythe MJ, Zhang Q, Vaughan K, de Castro R, Salimi N, Bui HH, Lewinsohn DM, Ernst JD, Peters B, Sette A. An analysis of the epitope knowledge related to Mycobacteria. Immunome Res 2007, 3:10. 10.1186/1745-7580-3-10, 2228276, 18081934.
29. Contini S, Pallante M, Vejbaesya S, Park MH, Chierakul N, Kim HS, Saltini C, Amicosante M. A model of phenotypic susceptibility to tuberculosis: deficient in silico selection of Mycobacterium tuberculosis epitopes by HLA alleles. Sarcoidosis Vasc Diffuse Lung Dis 2008, 25(1):21-28.
30. Sturniolo T, Bono E, Ding J, Raddrizzani L, Tuereci O, Sahin U, Braxenthaler M, Gallazzi F, Protti MP, Sinigaglia F, et al. Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices. Nat Biotechnol 1999, 17(6):555-561. 10.1038/9858, 10385319.
31. Liu W, Meng X, Xu Q, Flower DR, Li T. Quantitative prediction of mouse class I MHC peptide binding affinity using support vector machine regression (SVR) models. BMC Bioinformatics 2006, 7:182. 10.1186/1471-2105-7-182, 1513606, 16579851.
32. Wan J, Liu W, Xu Q, Ren Y, Flower DR, Li T. SVRMHC prediction server for MHC-binding peptides. BMC Bioinformatics 2006, 7:463. 10.1186/1471-2105-7-463, 1626489, 17059589.
33. Guan P, Doytchinova IA, Zygouri C, Flower DR. MHCPred: A server for quantitative prediction of peptide-MHC binding. Nucleic Acids Res 2003, 31(13):3621-3624. 10.1093/nar/gkg510, 168917, 12824380.
34. Guan P, Doytchinova IA, Zygouri C, Flower DR. MHCPred: bringing a quantitative dimension to the online prediction of MHC binding. Appl Bioinformatics 2003, 2(1):63-66.
35. Hattotuwagama CK, Guan P, Doytchinova IA, Zygouri C, Flower DR. Quantitative online prediction of peptide binding to the major histocompatibility complex. J Mol Graph Model 2004, 22(3):195-207. 10.1016/S1093-3263(03)00160-8, 14629978.
36. Cui J, Han LY, Lin HH, Tang ZQ, Jiang L, Cao ZW, Chen YZ. MHC-BPS: MHC-binder prediction server for identifying peptides of flexible lengths from sequence-derived physicochemical properties. Immunogenetics 2006, 58(8):607-613. 10.1007/s00251-006-0117-2, 16832638.
37. Nielsen M, Lundegaard C, Lund O. Prediction of MHC class II binding affinity using SMM-align, a novel stabilization matrix alignment method. BMC Bioinformatics 2007, 4;8:238.
38. Loffredo JT, Sidney J, Piaskowski S, Szymanski A, Furlott J, Rudersdorf R, Reed J, Peters B, Hickman-Miller HD, Bardet W, et al. The high frequency Indian rhesus macaque MHC class I molecule, Mamu-B*01, does not appear to be involved in CD8+ T lymphocyte responses to SIVmac239. J Immunol 2005, 175(9):5986-5997.
39. Lian W, Juan L, Fei L. Prediction of MHC Class II Binding Peptides Using a Multi-Objective evolutionary Algorithm. International Conference on Computational Intelligence and Security: 2007 2007, 101-104.
40. Xiang Z. Vaxign: a web-based vaccine target design program for reverse vaccinology. Porcedia in Vaccinology 2009, 1:1-7.
41. ProPred: MHC Class II Binding Peptide Prediction Server. , http://www.imtech.res.in/raghava/propred/
42. Bui HH, Sidney J, Peters B, Sathiamurthy M, Sinichi A, Purton KA, Mothe BR, Chisari FV, Watkins DI, Sette A. Automated generation and evaluation of specific MHC binding predictive tools: ARB matrix applications. Immunogenetics 2005, 57(5):304-314. 10.1007/s00251-005-0798-y, 15868141.
43. IEDB Analysis Resource: MHC - II binding predictions (ARB). , http://tools.immuneepitope.org/analyze/html/mhc_II_binding.html
44. MHCPred version 2.0. , http://www.darrenflower.info/mhcpred/
45. Singh H, Raghava GP. ProPred: prediction of HLA-DR binding sites. Bioinformatics 2001, 17(12):1236-1237. 10.1093/bioinformatics/17.12.1236, 11751237.
46. Reche PA, Glutting JP, Zhang H, Reinherz EL. Enhancement to the RANKPEP resource for the prediction of peptide binding to MHC molecules using profiles. Immunogenetics 2004, 56(6):405-419. 10.1007/s00251-004-0709-7, 15349703.
47. RankPep: prediction of binding peptides to Class I and Class II MHC molecules. , http://bio.dfci.harvard.edu/RANKPEP/
48. NetMHCII 2.0 Server. , http://www.cbs.dtu.dk/services/NetMHCII/
49. SVRMHC sever: A SVR-based prediction server for MHC-binding peptides. , http://svrmhc.biolead.org/
50. Vaxign Vaccine Design. , http://www.violinet.org/vaxign/index.php
51. NetMHCIIpan Server. , http://www.cbs.dtu.dk/services/NetMHCIIpan/
52. Kim HS, Park MH, Song EY, Park H, Kwon SY, Han SK, Shim YS. Association of HLA-DR and HLA-DQ genes with susceptibility to pulmonary tuberculosis in Koreans: preliminary evidence of associations with drug resistance, disease severity, and disease recurrence. Hum Immunol 2005, 66(10):1074-1081. 10.1016/j.humimm.2005.08.242, 16386650.
53. Lombard Z, Dalton DL, Venter PA, Williams RC, Bornman L. Association of HLA-DR, -DQ, and vitamin D receptor alleles and haplotypes with tuberculosis in the Venda of South Africa. Hum Immunol 2006, 67(8):643-654. 10.1016/j.humimm.2006.04.008, 16916662.
54. Ravikumar M, Dheenadhayalan V, Rajaram K, Lakshmi SS, Kumaran PP, Paramasivan CN, Balakrishnan K, Pitchappan RM. Associations of HLA-DRB1, DQB1 and DPB1 alleles with pulmonary tuberculosis in south India. Tuber Lung Dis 1999, 79(5):309-317. 10.1054/tuld.1999.0213, 10707259.
55. Sriram U, Selvaraj P, Kurian SM, Reetha AM, Narayanan PR. HLA-DR2 subtypes & immune responses in pulmonary tuberculosis. Indian J Med Res 2001, 113:117-124.